(19)
(11) EP 4 460 332 A2

(12)

(88) Date of publication A3:
21.09.2023

(43) Date of publication:
13.11.2024 Bulletin 2024/46

(21) Application number: 23737701.5

(22) Date of filing: 04.01.2023
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
C07K 16/28(2006.01)
A61K 33/243(2019.01)
C07K 16/30(2006.01)
A61P 35/00(2006.01)
A61K 39/395(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 47/68031; A61K 47/6849; A61K 47/6851; A61P 35/00; C07K 16/2803; C07K 2317/21; A61K 2039/545; A61K 2039/505
(86) International application number:
PCT/US2023/060062
(87) International publication number:
WO 2023/133388 (13.07.2023 Gazette 2023/28)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 05.01.2022 US 202263296831 P
28.01.2022 US 202263304136 P

(71) Applicants:
  • Agensys, Inc.
    Northbrook, IL 60062 (US)
  • Seagen Inc.
    Bothell, WA 98021 (US)

(72) Inventors:
  • CARRET, Anne-Sophie
    Bothell, WA 98021 (US)
  • ABIDOYE, Oyewale, O.
    Bothell, WA 98021 (US)

(74) Representative: Jones Day 
Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11
80538 München
80538 München (DE)

   


(54) METHODS FOR TREATING MUSCLE INVASIVE UROTHELIAL CANCER OR MUSCLE INVASIVE BLADDER CANCER WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS